Emphasys on the Block after FDA Panel Rejection
This article was originally published in Start Up
Executive Summary
Emphasys Medical, following negative recommendation from an FDA panel, put itself up for sale.
You may also be interested in...
Asthmatx Following the Leaders In Defining Alair Sales Strategy
Asthmatx is adopting the commercial strategy of high profile successes including Kyphon, Acclarent, Novacept, Fox Hollow Technologies to roll out its Alair broncial thermoplasty system, which recently received approval from the FDA.
Dealmaking in 2009: A Look Back and A Glance Ahead
This article was excerpted from "Top Device Stories of 2009: A Year of Economic Revival and Regulatory Risk," IN VIVO, January 2010.
Dealmaking in 2009: A Look Back and A Glance Ahead
This article was excerpted from "Top Device Stories of 2009: A Year of Economic Revival and Regulatory Risk," IN VIVO, January 2010.